Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Spike protein of SARS-CoV-2 |
Clinical data | |
Trade names | Xevudy |
Other names | VIR-7831, GSK4182136 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621037 |
License data |
|
Pregnancy category | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
DrugBank | |
UNII | |
KEGG |
Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2.[10][12][13] It was developed by GlaxoSmithKline and Vir Biotechnology, Inc.[12][14] Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.[12][13][15]
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.[10]
Although Sotrovimab was used world-wide against SARS-CoV-2, including in the United States under an FDA emergency use authorization (EUA), the FDA canceled the EUA in April 2022 due to lack of efficacy against the Omicron variant. [16]
TGA provisional approval
was invoked but never defined (see the help page).Xevudy CMA
was invoked but never defined (see the help page).FDA 20220405
was invoked but never defined (see the help page).